Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|21|3821-3829

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.21, 2013-11, pp. : 3821-3829

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 160-169

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF,KIT and NRAS mutations and expression of c‐KIT, phosphorylated extracellular signal‐regulated kinase and phosphorylated AKT in Japanese melanoma patients

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 5, 2015-05 ,pp. : 477-484

John Wiley & Sons Inc

Access to resources Recommend Favorite

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-05 ,pp. : 297-300

Karger

Access to resources Recommend Favorite

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

By  

Oncology, Vol. 93, Iss. 3, 2017-06 ,pp. : 164-176

Karger

Access to resources Recommend Favorite